NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $13 | $99 | $149 | $41 |
| - Cash | $23 | $53 | $32 | $10 |
| + Debt | $6 | $7 | $0 | $0 |
| Enterprise Value | -$4 | $52 | $117 | $31 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$33 | -$26 | -$17 | -$27 |
| % Margin | – | – | – | – |
| Net Income | -$34 | -$26 | -$17 | -$27 |
| % Margin | – | – | – | – |
| EPS Diluted | -21.08 | -18.8 | -17.6 | -65.49 |
| % Growth | -12.1% | -6.8% | 73.1% | – |
| Operating Cash Flow | -$29 | -$19 | -$11 | -$3 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$29 | -$20 | -$11 | -$3 |